BioCentury
ARTICLE | Regulation

Regulators agree on endpoints for COVID-19 therapeutics trials

July 31, 2020 10:29 AM UTC

International regulators have agreed upon the best endpoints for use in clinical trials for COVID-19 therapeutics, with mortality the key endpoint for hospitalized patients, while testing in mild patients should focus on disease progression or hospitalization rates.

The International Coalition of Medicines Regulatory Authorities (ICMRA) published a report from their July 20 workshop that discussed which endpoints would be acceptable for trials of COVID-19 therapeutics...